Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable Recruiting Phase 1 / 2 Trials for Ruxolitinib (DB08877)

IndicationStatusPhase
DBCOND0029236 (Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02158858A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With MyelofibrosisTreatment